Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation

This article was originally published in The Gray Sheet

Executive Summary

FDA formally classifies immunomagnetic circulating cancer cell selection and enumeration systems as Class II with special controls in a May 11 final rule
Advertisement

Related Content

Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
Advertisement
UsernamePublicRestriction

Register

MT020234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel